ProCE Banner Activity

Biomarkers for Immunotherapy in SCLC: Where Are We and Where Are We Going?

Multimedia
Watch this short video to get up to date on the role of biomarkers in predicting benefit of immune checkpoint blockade during treatment of extensive-stage SCLC.

Released: February 01, 2021

Expiration: January 31, 2022

Share

Faculty

Benjamin Levy

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Learning Objectives

  • Plan treatment strategies for patients with extensive-stage SCLC that include immune checkpoint inhibitor combinations
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor combinations in lung cancer

Faculty Disclosure

Primary Author

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Benjamin Levy, MD, has disclosed that he has received consulting fees from AstraZeneca, Lilly, Merck, Novartis, Pfizer, and Takeda.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.